Ken Griffin Dyne Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2025 May 15, 2025	BUY	$10.46 - $25.46 $109,830 - $267,330	10,500 Added 45.85%	33,400 $349,000
Q4 2024 Feb 14, 2025	BUY	$23.56 - $35.55 $51,832 - $78,210	2,200 Added 10.63%	22,900 $539,000
Q3 2024 Nov 14, 2024	BUY	$31.94 - $47.04 $392,862 - $578,592	12,300 Added 146.43%	20,700 $743,000
Q2 2024 Aug 14, 2024	SELL	$23.65 - $35.63 $279,070 - $420,434	-11,800 Reduced 58.42%	8,400 $296,000
Q1 2024 May 15, 2024	BUY	$13.06 - $29.18 $14,366 - $32,098	1,100 Added 5.76%	20,200 $573,000
Q4 2023 Feb 14, 2024	BUY	$6.62 - $13.64 $86,060 - $177,320	13,000 Added 213.11%	19,100 $254,000
Q3 2023 Nov 14, 2023	BUY	$8.6 - $12.18 $18,920 - $26,796	2,200 Added 56.41%	6,100 $54,000
Q2 2023 Aug 14, 2023	SELL	$8.53 - $14.28 $90,418 - $151,368	-10,600 Reduced 73.1%	3,900 $43,000
Q1 2023 May 15, 2023	SELL	$10.88 - $15.0 $616,896 - $850,500	-56,700 Reduced 79.63%	14,500 $167,000
Q4 2022 Feb 14, 2023	BUY	$9.37 - $13.8 $321,391 - $473,340	34,300 Added 92.95%	71,200 $825,000
Q3 2022 Nov 14, 2022	BUY	$7.2 - $15.17 $265,680 - $559,773	36,900 New	36,900 $469,000

217

116M

322K

66.2K

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $602M
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.